Axovant Sciences Ltd (NASDAQ:AXON) – Analysts at Oppenheimer issued their Q2 2019 earnings per share (EPS) estimates for Axovant Sciences in a note issued to investors on Wednesday, August 8th. Oppenheimer analyst J. Olson expects that the biotechnology company will earn ($0.52) per share for the quarter. Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Axovant Sciences’ Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.39) EPS, FY2019 earnings at ($1.81) EPS, FY2020 earnings at ($1.31) EPS, FY2021 earnings at ($1.03) EPS and FY2023 earnings at ($0.04) EPS.

Several other research analysts have also recently commented on the company. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $5.50 target price for the company in a research report on Monday, June 11th. ValuEngine cut Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Monday, June 11th. Jefferies Financial Group raised their target price on Axovant Sciences from $3.00 to $5.00 and gave the stock a “hold” rating in a research report on Monday, June 11th. HC Wainwright reaffirmed a “buy” rating on shares of Axovant Sciences in a research report on Thursday, June 7th. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $4.00 target price on shares of Axovant Sciences in a research report on Wednesday, June 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $11.70.

AXON opened at $2.07 on Monday. Axovant Sciences has a 1-year low of $1.02 and a 1-year high of $27.98. The company has a debt-to-equity ratio of 1.48, a current ratio of 2.34 and a quick ratio of 2.34. The company has a market capitalization of $252.71 million, a PE ratio of -1.00 and a beta of -0.15.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.33).

A number of institutional investors have recently added to or reduced their stakes in AXON. BlackRock Inc. raised its stake in Axovant Sciences by 99.8% during the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after acquiring an additional 1,454,454 shares in the last quarter. Millennium Management LLC raised its stake in Axovant Sciences by 175.6% during the first quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock worth $1,770,000 after acquiring an additional 847,946 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Axovant Sciences by 183.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock worth $1,120,000 after acquiring an additional 320,450 shares in the last quarter. A.R.T. Advisors LLC raised its stake in Axovant Sciences by 148.9% during the first quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 249,074 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Axovant Sciences by 2,519.0% during the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 176,227 shares in the last quarter. Hedge funds and other institutional investors own 13.94% of the company’s stock.

In related news, Director George Bickerstaff acquired 25,000 shares of the company’s stock in a transaction on Thursday, August 9th. The stock was purchased at an average cost of $2.07 per share, for a total transaction of $51,750.00. Following the completion of the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $103,500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Global Investors Lp Viking acquired 14,285,714 shares of the company’s stock in a transaction on Tuesday, June 5th. The shares were bought at an average price of $1.75 per share, with a total value of $24,999,999.50. Following the completion of the purchase, the insider now directly owns 89,285,714 shares of the company’s stock, valued at $156,249,999.50. The disclosure for this purchase can be found here. Corporate insiders own 6.00% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.

Read More: Market Capitalization – What it Means for Investors

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.